



My News 🔔

Today's Paper

Local

Tasmania

National

World

Health

Opinion

Business

Entertainment

Lifestyle


Sport



Health Conditions Dementia

EXCLUSIVE

# Alzheimer's disease: Actinogen Medical



## New breakthrough Alzheimer's treatment on trial

A once-a-day pill that targets the production of the stress hormone cortisol in the brain... more

A once-a-day pill that could completely revolutionise the treatment of

Join the conversation (0 Comments)

protein that could completely revolutionise the treatment of Alzheimer's disease. The trial of the "holy grail" drug is being conducted by Australian company Actinogen Medical, which has spent the last decade developing the pill.

### More related stories

The trial of the "holy grail" drug is being conducted by Australian company Actinogen Medical, which has spent the last decade developing the pill.



Dementia

## Why it's thought these weight loss drugs may reduce risk of dementia

A new study has revealed that people on these weight loss drugs had a significantly lower risk of developing dementia, especially among women.



Jim Northey who has been taking part in a trial of a new Alzheimers wonder drug, pictured at home in Caloundra with wife Bev. Picture Lachie Millard

### I quit my job at 30 to care for my mum after her dementia diagnosis

The drug is being trialled across 35 sites in Australia and the US. Instead, I spent much of my time navigating a complex healthcare system.

“There are more Australians than US patients in the trial at this stage, so

#### My News Feed

[Read More >](#)

“It’s probably fair to say there’s roughly equal numbers from New South Wales



Participants include 81-year-old Caloundra man Jim Northey whose wife Bev said she had noticed significant improvement in her husband during the treatment, to the extent she believed he must have been given Xanamem rather than the placebo which some trialists receive

“Initially, I didn’t know if it was going to work but as we got going along, we could see some definite improvements in Jim,” she said.

tests they gave him. I could see some real improvements in him. I felt very confident he was either not getting any worse or certainly getting better.”



Netball

**Thunderbirds slay Vixens to boost threepeat hopes**



National

**D-Day for mushroom trial jury**



Menopause

**‘We refuse to be quiet’: Why menopausal women are speaking out**




#### Trending now

Tasmania

#### Read More

Music Tours



**Dementia** Dr Steven Curly is the CEO of Actinogen Medical. Picture: Supplied

Don't miss out on the headlines from Dementia. Followed categories will be added to My News.

Follow



Trial lead Associate Professor Michael Woodward OAM. Picture: Supplied

In a major development for dementia care, three of Melbourne's leading hospitals — Austin Health, Royal Melbourne Hospital, and The Alfred — are playing a pivotal role in testing the drug, as well as the Hammondcare Clinic in Malvern.

Unlike current Alzheimer's treatments that target amyloid plaques (the sticky protein long blamed for the disease), Actinogen is taking a radical new approach: targeting cortisol, the brain's key stress hormone.

The trial is being led by Austin Hospital's Associate Professor Michael Woodward OAM, one of the nation's most respected dementia experts.

"We've spent decades chasing amyloid with only marginal benefit," Professor Woodward said.


"If cortisol is the real driver of Alzheimer's symptoms, we could have a safer, simpler, and far more effective treatment on our hands — one that's homegrown, no less."

Alzheimer's disease, which results in worsening symptoms over a number of years, affected 411,100 Australians in 2023, according to Australian Institute of

Existing medication and antibody therapies for treating Alzheimer's disease include Amyloid drugs like Donanemab, which require monthly infusions and expensive PET scans, with the cost of treatment estimated to be between \$40,000 and \$80,000 per year.

### How **Xanamem** works

Xanamem is a once-a-day pill that targets the production of the stress hormone cortisol in the brain, helping to slow down the course of Alzheimer's disease and address cognitive decline.




Cortisol is produced in the nerve cells

Amyloid plaque

Excess cortisol is associated with memory loss, amyloid plaques and neurodegeneration - the hallmarks of Alzheimer's disease.

Xanamem is designed to prevent the excess production of cortisol in the frontal lobe and hippocampus - the areas of the brain that are most affected by Alzheimer's disease.



Frontal lobe

Hippocampus

This could extend to other dementias such as Lewy-Body disease, frontotemporal dementia, and dementia associated with Parkinson's disease.

Source: Actinogen Medical.

“So a once a day pill with much greater ease of use, convenience and no complicated monitoring, would be a game-changer,” Dr Gourlay said.

“We now started to talk about potentially just regular specialist doctors, and even in the future, potentially GPs prescribing the medication because of its safety. And particularly, as we anticipate, we’re basically developing [the drug] to be at least twice as good as these antibody therapies that were recently approved.”

Most of the investment for the drug has come from Australia, with Dr Gourlay saying that more than \$100 million has been invested in the drug already.

“There’s been a lot of people involved, and a lot of it has got to do with everybody’s got a family member with dementia somewhere in their family, typically,” he said.

“But it’s also the weight of evidence pointing to cortisol was enormous. We’ve already showed that it works in depression now, so hopefully next year, we show clearly that it has a big effect in helping slow Alzheimer’s.”

An open-label extension trial, in which all participants receive the active drug, will begin in early 2026.

More Coverage



Next steps for new Alzheimer’s breakthrough pill



Could this once-a-day pill halt the most common type of dementia?

Originally published as [Alzheimer’s disease: Actinogen Medical drug Xanamem acquires 100th patient in trial](#)

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription packages	About us	Help & Support	Herald Sun	Buy Search Sell Classifieds	
Group/Corporate Subscriptions	Meet the team	Story Tips	The Daily Telegraph	Foxsports	
The Mercury App	Job Opportunities	FAQs	The Courier Mail	Foxtel	
Today's Paper	Code of Conduct	Standards of practice	The Advertiser	Hipages	
Newsletters	Subscription FAQs	Letter to the Editor	news.com.au	Kayo	
Rewards	Subscription terms	Licensing & Reprints	The Australian	My Tributes	
	Financial Hardship Policy	Advertise with us	Geelong Advertiser	Punters	
			The Cairns Post	odds.com.au	
			Gold Coast Bulletin	racenet.com.au	
				Sky News	
				Coupons	

Townsville  
Bulletin  
The Chronicle  
NT News  
The Weekly  
Times  
CODE Sports

---

A NOTE ABOUT RELEVANT ADVERTISING: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2025. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#)   [Relevant ads opt-out](#)   [Cookie policy](#)   [Terms of use](#)